Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Vaxil Bio Ltd V.VXL

Alternate Symbol(s):  VXLLF

Healthcare Biotechnology
Vaxil Bio Ltd. is a Canada-based biotechnology company. The Company is focused on a drug discovery and development platform based on Signal Peptides (SPs) which the Company deploys to fight infectious diseases and cancer. The Company’s most advanced product, ImMucin, a MUC1 SP-derived vaccine, completed a Phase I/II clinical trial in multiple myeloma. The Company also has a SP-based COVID-19 vaccine candidate and a SP-based tuberculosis vaccine / treatment candidate. In addition, The Company has mAb candidates for the treatment of oncology and infectious diseases to be used alone, and in combination with other treatments. It has also initiated a pre-clinical program for a drug delivery polymer that targets high affinity E-selectin (P-Esbp), which the Company licensed for development and commercialization from BGN Technologies. It exploits the properties of SP domains on crucial proteins to develop targeted therapies against cancer targets and infectious disease pathogens.


TSXV:VXL - Post by User

Vaxil Bio Ltd
<< Previous
 Bullboard Posts
Next >>
User Avatar Image
(199)
•••
Post by Red~Oneon Jan 27, 2021 6:06pm
42 Views
Post# 32403244

The Market herald

The Market herald[url=https://https://themarketherald.ca/vaxil-provides-update-on-usamriid-oral-experiment-and-other-general-business-matters-2021-01-27/?utm_source=stockhouse.com&utm_medium=widget&utm_campaign=stockhouse.com%7Cwebpart_news%7Cnews_tab]News[/url]

  • Vaxil Bio Ltd. (VXL) provided an update on the progress of its cooperative research and development agreement with the US Army Medical Research Institute of Infectious Diseases on its COVID-19 vaccine
  • The Israeli biotech company said the mice received three scheduled vaccinations by December 31, 2020 and responded normally to the injections administered
  • Further monitoring will be done over the next weeks while the animals’ immune response continues
  • The company expects that the mice will be “challenged” with (exposed to) the COVID-19 virus at the end of the month followed by careful monitoring and testing
<< Previous
 Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities